Diagnosis, front line treatment and molecular monitoring of acute promyelocytic leukaemia.
Lo Coco
F
F
Department of Cellular Biotechnologies and Haematology, University La Sapienza of Rome, Italy. lococo@bce.med.uniroma1.it
Diverio
D
D
Avvisati
G
G
Mandelli
F
F
D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics; D002884:Chromosomes, Human, Pair 15 / Q000235:genetics / Q000648:ultrastructure; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics / Q000648:ultrastructure; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D005544:Forecasting; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000235:genetics; D015337:Multicenter Studies as Topic; D009363:Neoplasm Proteins / Q000235:genetics / Q000502:physiology; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000502:physiology; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D016879:Salvage Therapy; D014178:Translocation, Genetic; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D003561:Cytarabine; D014212:Tretinoin